QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Kamada Ltd. (KMDA)

Healthcare

No action
Fundamental
4
Sentiment
3
Technical
2

Do Nothing: 20-day average dollar volume of ~$703K is far below the $5,000,000 liquidity floor and the last three regular sessions average ~$452K, below the $1,500,000 recent-liquidity floor, so neither a pullback limit nor a breakout stop is admissible, and a confirmed 2026-11-09 earnings date also falls inside the 15-trading-day holding window (horizon 2026-11-10).

Analysis as of 2026-10-20· more than 2 trading days ago

Company overview

Kamada Ltd. is a biopharmaceutical company specializing in protein therapeutics derived from human plasma. It operates through proprietary products and distribution, offering treatments for various conditions including rabies, cytomegalovirus, and hepatitis B. Kamada collaborates with partners like Takeda and Kedrion Biopharma, and markets its products globally.

Fundamental

good
Fundamental4
Solid fundamentals

Kamada Ltd. is profitable with a net-cash balance sheet and improving margins, showing strong financial health.

A profitable, net-cash specialty plasma company growing revenue at a low-teens pace with expanding margins, nearly doubling operating cash flow, an unqualified audit and no going-concern or covenant issues. Valuation is modest (about 18.7x earnings, 8.9x EV/EBITDA, 7.6% free-cash-flow yield) and guidance was just raised, but customer/product concentration, Israel-based manufacturing risk, a larger arbitration counterclaim and a generous dividend payout are the offsets. Solid fundamentals with minor concerns.

Sentiment

fair
Sentiment3
Mixed sentiment

Sentiment is constructive but unconfirmed, with a fresh product catalyst yet to impact the tape significantly.

The dominant driver is a market-rewarded earnings cluster dated 2026-11-09 — record nine-month 2026 results, 2026 revenue and adjusted-EBITDA guidance raised, a first explicit double-digit 2027 growth outlook (announced), a $50M U.S. plasma supply agreement and a Stifel price-target raise — only partially absorbed eight days on, with the shares up ~6.9% on the print and all five scored in-window items positive (polarity_score ≈ +0.52). The sentiment delta is indeterminate because the 2026-08-19 → 2026-10-18 baseline scored only two unique on-topic items (below the three-item threshold); the Red-Flag Screen is clean and no cap was applied.

Technical

weak
Technical2
Weak trend

The stock is below key moving averages with low liquidity, indicating a weak and directionless trend.

Bounce-only tape (score 2): price 7.85 sits below the SMA20 8.13, SMA50 8.14, SMA200 8.02, EMA21 8.00 and WMA21 7.95, but has reclaimed EMA9 7.83, DEMA14 7.71, TEMA14 7.61 and the VWAP 7.82 off the 2026-10-14 swing low 7.46 and closed +3.2% on the session. MACD -0.15 is below its -0.10 signal (histogram -0.05, narrowing from -0.09 on 10-15); RSI14 45.8 and ADX14 18.0 describe a weak, directionless trend — a reflex bounce, not a confirmed reversal. Any entry is blocked upstream of the chart: 20-day average dollar volume is $703,121 (floor $5M), the last three regular sessions average ~$452,262 (floor $1.5M), and a confirmed 2026-11-09 earnings date sits inside the 15-trading-day holding window (horizon 2026-11-10).

You’re looking at 2026-10-20 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.